600713.SS
600713.SS
CNE000000KV1
NANJING PHARMACEUTICAL GP CO LT
Loading chart...
Elevated Business & Solvency Risk

Caution: In addition to price volatility, there are balance sheet risks due to higher debt or weaker liquidity (Health Score: 45/100).

Volatility Risk

Transparent evaluation of price volatility (SRI), Beta, and historical drawdowns.

Volatility Risk Score
7/7 Very High
7 / 7 SRI Price Fluctuation & Beta

Very high volatility or fundamental risks. Significant loss potential; strictly for aggressive investors. Moves noticeably less than the broader market (0.2x).

Beta (Market Relation)
0.2x
Defensive
Volatility (5Y p.a.)
28.3% p.a.
5-Year Horizon
Max Drawdown (5Y)
-36.9%
5-Year Horizon
Sharpe Ratio
-0.01
Return / Risk
Speculative / High Risk: Score Basis:

Multi-Horizon Risk & Performance Matrix

Historical volatility, drawdowns, and risk-adjusted return across 1, 3, 5, and 10 years.

High Volatility
Timeframe
Volatility (p.a.)
Max Drawdown
Sharpe Ratio
Return (p.a.)
1 Year — — — +3.6%
3 Years 26.5% -28.3% -0.06 +0.9%
5 Years 28.3% -36.9% -0.01 +2.2%
10 Years 26.4% -56.6% -0.29 -5.2%

Automated Risk & Health Notes (Red Flags)

Single Stock Risk: Investing in an individual stock carries full company and insolvency risk (no fund diversification).
Structurally High Volatility: Above-average fluctuations persist across 5 to 10 years (28.3% p.a.).
Historical Stress Test: Maximum peak-to-trough drawdown of -56.6% in the extended horizon.
ende